Anti-Diabetic Medications for the Pharmacologic Management of NAFLD
AbstractAs a chronic disease encompassing a wide spectrum of liver-related histologic damage, nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic with significant impacts on all-cause morbidity and mortality. Insulin resistance and type 2 diabetes mellitus predispose individuals to NAFLD and related complications. Therefore, timely intervention with anti-diabetic medications may prevent and delay the development of NAFLD or have a therapeutic implication. The focus of this review is to evaluate the evidence supporting the efficacy of anti-diabetic medications in the treatment of NAFLD. While many of these anti-diabetic agents have shown to improve biochemical parameters, their effect on hepatic histology is limited. Among anti-diabetic medications, only thiazolidinediones and glucagon-like peptide-1 receptor agonists demonstrate significant improvement in hepatic histology. View Full-Text
Share & Cite This Article
Cholankeril, R.; Patel, V.; Perumpail, B.J.; Yoo, E.R.; Iqbal, U.; Sallam, S.; Shah, N.D.; Kwong, W.; Kim, D.; Ahmed, A. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases 2018, 6, 93.
Cholankeril R, Patel V, Perumpail BJ, Yoo ER, Iqbal U, Sallam S, Shah ND, Kwong W, Kim D, Ahmed A. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases. 2018; 6(4):93.Chicago/Turabian Style
Cholankeril, Rosann; Patel, Vikram; Perumpail, Brandon J.; Yoo, Eric R.; Iqbal, Umair; Sallam, Sandy; Shah, Neha D.; Kwong, Waiyee; Kim, Donghee; Ahmed, Aijaz. 2018. "Anti-Diabetic Medications for the Pharmacologic Management of NAFLD." Diseases 6, no. 4: 93.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.